<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98941">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651858</url>
  </required_header>
  <id_info>
    <org_study_id>DW_SDF001</org_study_id>
    <nct_id>NCT01651858</nct_id>
  </id_info>
  <brief_title>Nurigra Chewable Tablet in Healthy Adult Male Volunteers</brief_title>
  <official_title>Nurigra Chewable Tablet in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics of sildenafil citrate in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>to Assess Pharmacokinetics</measure>
    <time_frame>24h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC and Cmax in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to Assess Safety</measure>
    <time_frame>24h after administration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, Physical exam, Vital sign, Laboratory, 12-lead-ECG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nurigra Chewable tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Viagra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nurigra Chewable tablet</intervention_name>
    <description>1 tablet of 100mg, once a day</description>
    <arm_group_label>Nurigra Chewable tablet</arm_group_label>
    <arm_group_label>Viagra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy and male subjects aged 20 to 45 years

          -  A Subject who was judged to be healthy by the investigator to participate in this
             study based on screening results (according to standard reference index updated
             recently)

          -  A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints.

        Exclusion Criteria:

          -  A subject with sign or symptoms or previously diagnosed disease of liver
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 25, 2012</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
